Clinical trials: Leukemia, Lymphoid, Acute
T-cell Lymphoma, NK-Cell Lymphoma
A Registry for People With T-cell Lymphoma
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma.
- Conditions
- T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia
- Trial name
- NCT05978141
- Testing
- Optional Blood Sample and Nail Sample
- Where
- 26 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02819583
- Testing
- PCAR-019 (anti-CD19 CAR-T cells)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
B-cell Acute Lymphoblastic Leukemia
A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC019F CAR-T cell immunotherapy in relapsed or refractory B-ALL.
- Trial name
- NCT04595162
- Testing
- GC019F
- Volunteers
- 12 people
- Sponsor
- Peking University Third Hospital
T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because…
- Conditions
- T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma, T-cell Leukemia, Lymphoma
- Trial name
- NCT06698003
- Testing
- Mogamulizumab
- Where
- 7 sites in United States
- Volunteers
- 134 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloid Leukemia, CML
Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
This prospective registry is initiated to follow up on the use of Iclusig® in patients with CML or Ph+ ALL in routine practice in Belgium.
- Conditions
- Chronic Myeloid Leukemia, CML, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia, Ph+ ALL
- Trial name
- NCT03678454
- Where
- 19 sites in Belgium
- Volunteers
- 80 people
- Sponsor
- Incyte Biosciences Benelux
HSCT, Ph+ ALL
Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL
To study the minimal residual disease (MRD) clearance rate of olverembatinib combined with inotuzumab ozogamicin as first-line consolidation chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic…
- Trial name
- NCT07443488
- Testing
- Olverembatinib+INO
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route…
- Trial name
- NCT05397496
- Testing
- PIT565
- Where
- 18 sites in United States, Belgium and 7 more
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
- Trial name
- NCT04029688
- Testing
- Idasanutlin, Venetoclax, Cyclophosphamide
- Where
- 14 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Acute Lymphoblastic Leukemia, Pancreatitis
PEG-Asparaginase Associated Pancreatitis, Hepatotoxicity and Hyperlipidemia in Children With ALL
The purpose of this study is to create a model enabling us to predict pancreatitis, hyperlipidemia and hepatotoxicity during treatment with PEG-Asparaginase in children with Acute Lymphoblastic Leukemia.
- Trial name
- AAP2008 (NCT01393249)
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cancer
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
RATIONALE: Methotrexate and glucocorticoid therapy, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant.
- Trial name
- NCT00357084
- Testing
- methotrexate, methylprednisolone, prednisone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphobkastic Leukemia, Leukemia
Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is characterized by the abnormal proliferation of immature precursor cells, disrupting normal hematopoiesis and causing severe anemia and thrombocytopenia due to genetic mutations.
- Conditions
- Acute Lymphobkastic Leukemia, Leukemia, Overall Survival
- Trial name
- EPOCH (NCT07258043)
- Testing
- Patients meeting criteria will receive DA-EPOCH via central line for 5 days every 21 days, with monitoring, supportive care, transfusions, prophylaxis, and G-CSF for 5 doses per cycle
- Where
- Mexico
- Volunteers
- 45 people
- Sponsor
- Hospital General de Mexico
Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria
Unrelated Donor Stem Cell Transplantation
The purpose of this study is to provide an opportunity for patients with malignancies or bone marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic progenitor cell transplantation using cells…
- Conditions
- Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT01364363
- Testing
- Allogeneic transplantation
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Scripps Health
T-cell Acute Lymphoblastic Leukemia
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
- Trial name
- NCT05289687
- Testing
- Daratumumab / Hyaluronidase Injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Eastern Cooperative Oncology Group
Acute Lymphoblastic Leukemia
TDM of Asparaginase in ALL2008
Asparaginase is a cornerstone in the treatment of ALL. In most contemporary protocols like in NOPHO ALL2008 prolonged asparaginase treatment has been implemented.
- Trial name
- NCT04843514
- Where
- 2 sites in Denmark
- Volunteers
- 765 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Hematologic Malignancy, Acute Myeloid Leukemia
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.
- Conditions
- Hematologic Malignancy, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03555955
- Testing
- CPX-351
- Where
- 13 sites in United States, Canada
- Volunteers
- 21 people
- Sponsor
- Jazz Pharmaceuticals
Hematologic Neoplasms
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
This trial will evaluate the safety and efficacy of post-transplant Cy and sirolimus following reduced intensity allogeneic SCT.
- Trial name
- NCT01244906
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Northside Hospital, Inc.
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Leukemia
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00060255
- Testing
- busulfan, carboplatin, carmustine
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Roswell Park Cancer Institute
MRD-positive, Acute Lymphoblastic Leukemia
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
To evaluate the safety and efficacy of CD19/CD22 Bispecific chimeric antigen receptor (CAR)-T for the treatment of measurable residual disaese (MRD)-positive B cell acute lymphoblastic leukemia.
- Trial name
- NCT03919526
- Testing
- anti-CD19/CD22 CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
This study evaluates the efficacy of high-dose post-transplantation cyclophosphomide as graft-versus-host disease (GVHD) prophylaxis after allogeneic stem cell transplantation in patients with different risk of GVHD.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT02294552
- Testing
- Cyclophosphamide, Busulfan, Fludarabine monophosphate
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Ivan S Moiseev
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.